Several receptor tyrosine kinases (TKs) are involved in the pathogenesis of acute myeloid leukemia (AML). Here, we have assessed the expression of the Recepteur d'Origine Nantais (RON) in leukemic cell lines and samples from AML patients. In a series of 86 AML patients, we show that both the full length and/or the short form (sf) of RON are expressed in 51% and 43% of cases, respectively. Interestingly, sfRON is not expressed in normal CD34 þ hematopoietic cells and induces part of its oncogenic signaling through interaction with the Src kinase Lyn. sfRON-mediated signaling in leukemic cells also involves mTORC1, the proapoptotic bcl2-family member, BAD, but not the phosphatidylinositol 3-kinase/Akt pathway. Furthermore, the expression of sfRON was specifically downregulated by 5-azacytidine (AZA). Conversely, AZA could induce the expression of sfRON in sfRON-negative leukemic cells suggesting that the activity of this drug in AML and myelodysplastic syndromes could involve modulation of TKs. cMET/RON inhibitors exhibited an antileukemic activity exclusively in AML samples and cell lines expressing sfRON. These results might support clinical trials evaluating cMET/RON inhibitors in AML patients expressing sfRON.
INTRODUCTION
Activation of tyrosine kinases (TKs) is frequently observed in acute myeloid leukemia (AML) and has a crucial role in leukemogenesis in cooperation with other oncogenic events such as transcription factors inactivation. 1 Mutations observed in most of the cases result in a constitutive activation of the TK activity promoting cell proliferation and survival as illustrated by the recurrent mutations of the Fms-like TK 3-receptor. 2 Selective inhibition of these TKs by small molecule represents a therapeutic strategy tested in clinical trials. 3 Although mutations of TKs are likely to be critical to the leukemic clone, other mechanisms of TK activation might also contribute to cell proliferation. A high level of tyrosine phosphorylation is observed in virtually all AML samples, whereas known mutations of TKs encompass only half of the cases, suggesting that other TKs could act as key activators of signal transduction pathways in AML. 4 The cMET-related receptor TK RON (Recepteur d'Origine Nantais) is expressed in most epithelial tissues but also in normal hematopoietic CD34 þ cells and in macrophages. RON or macrophage-stimulating 1 receptor, is a 185 kDa protein constituted of an extracellular domain, a single pass hydrophobic membrane spanning domain and an intracellular region. RON is expressed as a heterodimeric receptor, consisting of a 35 kDa a-chain and a 150 kDa b-chain. The a-chain is entirely extracellular whereas the b-chain contains the extracellular, transmembrane and intracellular regions of the receptor including the TK domain. The 50-amino-acid TK domain of RON shares 80% identity with the cMET TK domain. 5 In physiological conditions, RON is activated by its ligand, the macrophage-stimulating protein or hepatocyte growth factor-like, and regulates cell proliferation, migration and survival. The binding of macrophage-stimulating protein/ hepatocyte growth factor-like to RON induces the receptor dimerization and trans-autophosphorylation of tyrosine residues (1238/1239) in the TK domain, leading to the tyrosine phosphorylation of key C-terminal residues (1353/1360) providing docking sites for adaptor molecules and initiation of signaling responses involving the phosphatidylinositol 3 (PI3)-kinase/Akt, b-catenin, Ras, mitogen-activated protein kinase and Janus kinase/signal transducers and activators of transcription pathways. The human RON gene gives rise to two transcripts of 5.0 and 2.0 kb coding for the full length (fl) and short form (sf) of the receptor, respectively. 6 RON expression could also be associated with a complex methylation pattern of two distinct CpG islands in the RON proximal promoter, which could induced the expression of a constitutively active sfRON. 7 sfRON is deleted at the C terminus, lacks the extracellular domain but retains the transmembrane and intracellular domains of the protein. This truncated form of RON has been detected in normal tissues but not in hematopoietic cells. 6 sfRON is also expressed in several human tumor cells lines in which it induces a more aggressive phenotype. [8] [9] [10] However, the signal transduction induced by the short form has not been well described compared with the full-size receptor.
The role of RON in AML has received little attention although sfRON has been detected in some AML cell lines. 8 sfRON had also been previously identified in mice susceptible to Friend virusinduced erythroleukemia. 11 In this paper, we assessed the global expression of both flRON and sfRON but also the cellular functions and regulation of sfRON in AML. 1 
RNA extraction and reverse transcriptase-PCR
Cytoplasmic mRNA was prepared using the TRIzol Reagent from Invitrogen (Life Technology, Carlsbad, CA, USA). Retrotranscription was carried out with SuperScript III cDNA synthesis kit following the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). To examine RON transcript expression, PCR was performed as described. 8 To rule out the possibility that the identified reverse transcriptase-PCR products could derive from unprocessed nuclear RNA, cytoplasmic RNA was purified, control amplifications were performed with antisense primers corresponding to other intron sequences (data not shown) and showed that unprocessed RNA was not present. All PCR were performed with DNA polymerase GoTaq (Promega).
Western blotting and immunoprecipitation
Western blotting was performed as previously described. 12 For immunoprecipitations, 10 7 cells were lysed with 750 ml of lysis buffer 20 mM Tris/HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, pH 7,4, 2 mM sodium orthovanadate, 1 mM leupeptin and 1 mM aprotinin. After 30 min on ice, cells lysates were sonicated three times for 10 s and centrifuged at 12 000 g for 10 min. After centrifugation, supernatants were incubated with appropriate antibodies for 2 h at 4 1C on a rocking platform and incubated with 25 ml protein G or A Dynabeads (1/5 vol/vol) (Invitrogen) for one additional hour. Immune complexes were washed three times with lysis buffer. The immunocomplex or total cell lysates were lysed in a Laemmli's buffer. Immunoprecipitates or cell lysates were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, electrotransferred to nitrocellulose membranes and detected by immunoblotting using the enhanced chemiluminescence lighting system (Perkin Elmer, Shelton, CT, USA). Lyn and RON antibodies were biotinylated using the BiotinTag Micro Biotinylation Kit (Sigma-Aldrich) and detected using a horseradish peroxidase coupled to streptavidin (Pierce, Rockford, IL, USA).
Small interfering RNA (siRNA) experiments
Fresh AML cells and cell lines were transfected using the Amaxa nucleofection technology (Lonza, Kö ln, Germany). Leukemic cells (2 Â 10 6 ) in 100 ml of solution kit V or R were mixed with 200 mM siRNA Cell proliferation assay siRNA transfected or inhibitors treated cell lines and AML samples were diluted at a final concentration of 5 Â 10 5 cells/ml or 1 Â 10 6 AML cells, respectively. Cells (100 ml) were seeded in triplicate in 96-well plates. In all, 20 ml MTS (Promega) was then added to each well and incubated at 37 1C for 3 h.
Flow cytometric analysis
After incubation 12 h with or without cMET inhibitors, 3 Â 10 5 cells were washed twice with cold phosphate-buffered saline with 1% bovine serum albumin, and then resuspended in 300 ml of annexin-V binding buffer. Two microliters of annexin-V-PB (Biolegend, San Diego, CA, USA) were added for 15 min at room temperature in the dark. 5.10 5 AML patient cells invalidated for sfRon were prepared as above. Two microliters of annexin-V-fluorescein isothiocyanate (BD Pharmingen, San Diego, CA, USA) and 2 ml of 7-aminoactinomycin D (Sigma, St Louis, MO, USA) were added. The percentage of apoptotic cells was assessed using an LSRII cytometer (Beckman Coulter, Miami, FL, USA). 13 Clonogenic assays AML cells (10 6 cells/ml) were grown in H4230 Stem Cell Technologies methyl cellulose medium (Stem Cell Technologies, Vancouver, BC, Canada) and increasing concentrations of cMET inhibitors as described. 4, 12 CD34 þ human bone marrow cells were plated in 35-mm Petri dishes in duplicate with or without SU-11274. Cells were incubated for 14 days in a humidified CO 2 incubator. Colonies were then scored under an inverted microscope.
Confocal microscopy AML cells, KG1 and HL-60 were fixed with 4% (w/v) paraformaldehyde for 10 min at 4 1C, washed with phosphate-buffered saline and then permeabilized with phosphate-buffered saline-Saponine-SVF for 20 min. Cells were then incubated for 30 min with primary antibody. After three washes in 3% bovine serum albumin-phosphate-buffered saline, secondary antibody (anti-rabbit Alexa Fluor 488) was added for 30 min. Cells were then plated on poly-L-lysine precoated slides. The coverslips were mounted with Vectashield DAPI (Vector Laboratories Inc., Burlingame, CA, USA). Preparations were analyzed by confocal laser scanning using a Zeiss LSM710 (Carl Zeiss, Jena, Germany) equipped with a 63 Â objective.
Statistics
Results are expressed as means±s.e.m. Statistical analyses were performed by Mann-Whitney or Student's t-test with Prism 4 software (GraphPad Software Inc., La Jolla, CA, USA). Differences were considered as significant for P-values of p0.05. *; **; *** correspond to Po0.05; Po0.01; Po0.001, respectively.
RESULTS

Expression, activation and localization of RON in myeloid leukemic cell lines
We first assessed the expression of RON both at mRNA and protein levels in leukemic cell lines. The two forms of RON are expressed at the mRNA level in KG1a and KG1 but not in HL60 and U937 whereas only sfRON is detected in TF-1 ( Figure 1a ). This expression was confirmed at the protein level after immunoprecipitation by the detection of 55 and 150 kDa bands corresponding to sfRON and flRON, respectively ( Figure 1b) . A phosphospecific antibody recognizing the phosphorylation of RON on Y1353 was used to study the activation status of sfRON and flRON. Only sfRON was phosphorylated on Y1353 in KG1, KG1a and in TF-1, whereas flRON was undetectable ( Figure 1c ). This phosphorylation was strongly inhibited by the cMET inhibitor SU-11274 ( Figure 1d ). We also stimulated KG1 with the ligand of RON. Macrophagestimulating protein/hepatocyte growth factor-like increased the basal level of phosphorylation of flRON probed either with the antipTyr (data not shown) or with the phosphospecific Y1353 antibody (Figure 1e ). sfRON remained highly phosphorylated on Y1353 with or without macrophage-stimulating protein indicating that sfRON is activated in KG1 regardless the presence of the ligand. However, the proliferation rate of KG1 was not modified as compared with untreated cells (Figure 1e ). We then analyzed RON localization in KG1 by confocal microscopy ( Figure 1f ). RON appeared to be distributed over the entire plasma membrane and also in the cytoplasm in KG1. Of note, cMET was hardly detectable by western blotting in all leukemic cell lines tested (Supplementary Figure S1) . Thus, these experiments show a particular pattern of RON expression in AML cell lines and suggest that sfRON is the form bearing the constitutive activity of the kinase.
Activity of cMET inhibitors and RON siRNA in leukemic cell lines To assess the role of RON in the proliferation and survival of leukemic cell lines, we used two cMET inhibitors, which are also active against RON. 14 We observed that both inhibitors affected KG1 cell growth in a time and dose-dependent manner with an IC50 of 4.3 mM and 5.6 mM at 72 h for SU-11274 and PHA-665752, respectively ( Figure 2a ). In contrast, these two inhibitors had no effect on HL60 growth. The inhibition of KG1 growth was mainly due to apoptosis as demonstrated by the increase in the percentage of annexin-V-positive cells after 12 h of treatment with SU-11274 (Figure 2b ). BAD, a pro-apoptotic member of the Bcl-2 family, which is inactivated by phosphorylation in AML was dephosphorylated on SU-11274 treatment (see Figure 3a) . 15 Moreover, the RON siRNA that abrogated the expression of both flRON and sfRON reduced the growth of KG1 (Figures 2c and d) . To confirm these results, we have performed these functional experiments in three others cell lines. cMET inhibitors inhibited cell proliferation in KG1a and TF-1, whereas no significant impact was observed in U937. For knock down experiments, three different siRNAs have been used with similar results (Supplementary Figures S2-S4 and Figure 5 ).
sfRON signaling in leukemic cell lines A major cell survival pathway usually activated by RON is the PI3-kinase/Akt pathway, which is activated in most AML samples. 16 SU-11274 inhibited the phosphorylation of mammalian target of rapamycin complex 1 (mTORC1) targets (4E-BP1 and RPS6) but not of Akt (Figure 3a) . SU-11274 also inhibited the Src kinase Lyn on its activation site Y396. We have recently shown that Lyn is constitutively activated in AML and contributes to cell proliferation through mTORC1 activation in a PI3-kinase/Akt-independent manner. 4 However, the mechanisms of Lyn activation in leukemic cells remain unknown. The dephosphorylation of Lyn by SU-11274 led us to investigate the relationship between RON and Lyn by assessing their potential interaction by co-immunoprecipitation. Only sfRON was associated with Lyn and this interaction disappeared with the knock down of Lyn expression using a specific siRNA (Figure 3b) . Furthermore, the depletion of Lyn decreased the phosphorylation of sfRON on Y1353, suggesting a bi-directional functional link between these two kinases. Indeed, RON knock down abrogated the phosphorylation of Lyn in KG1 cells without affecting Akt phosphorylation as observed with SU-11274 (Figure 3c ). Dasatinib, a dual BCR-ABL/Src kinase family inhibitor that potently inhibited Lyn activity affected the phosphorylation of sfRON on Y1353 (Figure 3d ). Altogether, these results suggested that Lyn and sfRON interact physically and regulate each other. Consistent with our previous works showing that Lyn regulates mTORC1 in AML cells, we show here that sfRON inhibition induces the dephosphorylation of mTORC1 targets. 4 To fully investigate sfRON signaling in leukemic cells, we also modulated its endogenous Figure S5) . Conversely, in the sfRON-negative cell line U937, AZA used in the same conditions induced the expression of sfRON. At this concentration, the growth of U937 was weakly affected (Figure 4b ). AZA treatment of KG1 cells was associated with the dephosphorylation of Lyn on Y396, sfRON on Y1353 and mTORC1 targets in accordance with results previously obtained with RON siRNA and cMET inhibitors. Moreover, the global profile of tyrosine phosphorylation in KG1 was reduced after AZA treatment in a similar manner than previously described after Lyn inhibition (Figure 4c ). 4 Conversely, the expression of sfRON (phosphorylated on Y1353) induced by AZA in U937 was associated with a significant increase in the global profile of tyrosine phosphorylation and the phosphorylation of Lyn and mTORC1 targets. We then treated KG1 and U937 with AZA, SU-11274 alone and in combination. Although AZA þ SU-11274 did not display additive or synergistic effect on the cell growth of KG1, only the combination significantly reduced the cell growth of U937 after 72 h of incubation, a time where sfRON protein expression has been induced by AZA (Figure 4d ).
Finally, as the TF-1 cell line appears to express only sfRON, we recapitulated most of the aforementioned experiments in this cell line ( Figure 5 ).
Pattern of expression of RON and constitutive activation of sfRON in AML specimens
The expression of sfRON and flRON was assessed by reverse transcriptase-PCR on bone marrow samples from 86 AML patients whose characteristics are summarized in Table 1 and were as follows: flRON only (20%), sfRON only (12%), flRON þ sfRON (31%) and no RON (37%). The main characteristics of patients including cytogenetics and molecular data were not statistically different between sfRON-positive and -negative patients. Importantly, only flRON was expressed in normal bone marrow CD34 þ cells from healthy donors whereas sfRON was undetectable (Figure 6a Short form-RON expression in AML C Fialin et al phosphorylated on Y1353 in 12/12 samples in a SU-11274 sensitive manner whereas flRON was undetectable using this antibody (Figures 6a and b) . Moreover, knock down of RON by siRNA in samples #48, #78 and #87 was associated with the dephosphorylation of Lyn and RPS6 (#78) in accordance with the results observed in KG1 (Figure 6c ). Finally, we modulated the expression of sfRON by AZA in primary samples. AZA induced the downregulation of sfRON expression that was correlated with a dephosphorylation of Lyn and mTORC1 targets and with a decrease in tyrosine phosphorylations (Figure 6d) . Conversely, AZA induced the expression of sfRON that was phosphorylated on Y1353 in sfRON-negative samples. sfRON signaling was also induced on AZA treatment. Furthermore, treatment of sfRONpositive and -negative samples with AZA, SU-11274 alone and in combination showed that only the combination was able to reduce the cell growth of sfRON-negative samples whereas it had no effect on sfRON-positive samples (Figure 6e ).
Antileukemic activity of cMET inhibitors and RON siRNA in primary AML samples We analyzed the effect of SU-11274 and PHA-665752 on the survival and proliferation of AML samples and normal CD34 þ cells. Incubation of AML samples with 2 and 5 mM of SU-11274 or PHA-665752 for 72 h significantly reduced the cellular viability by 50% in samples expressing sfRON (n ¼ 15) whereas samples that did not express sfRON (n ¼ 9) were insensitive (Figure 7a ). Of note, the unique sample tested expressing flRON but not sfRON, did not respond to SU-11274 and PHA-665752 (data not shown). In sfRON þ samples, SU-11274 induced apoptosis both in leukemic bulk and in the immature CD34 þ CD38 À CD123 þ sub-population (Figure 7b) . We also used a methylcellulose-based clonogenic assay in 13 AML samples. Interestingly, five RON-negative samples and the one expressing flRON alone did not produce any colonyforming unit-leukemia (CFU-L). From seven samples expressing sfRON, five produced CFU-L whose growth was inhibited by SU-11274 and PHA-665752 in a dose-dependent manner (Figure 7c ). We then studied the effect of SU-11274 and PHA-665752 on the capacity of normal CD34 þ cells to generate granulo-monocytic (CFU-GM) and monocytic (CFU-M) colonies. No significant change and no dose-response were observed in the number of CFU-GM and CFU-M on treatment with cMET inhibitors (Figure 7d) . Furthermore, the knock down of RON-induced apoptosis in three samples and reduced the clonogenic properties of samples #48 and #87 (Figures 7e and f) . It is noteworthy that, in sample #87 expressing only sfRON, RON siRNA reduced the clonogenicity in a comparable magnitude to sample #48, which expressed both forms. Altogether, these results show that, in most cases, cMET inhibitors target AML progenitors expressing sfRON whereas sparing both RON-negative AML samples and normal progenitors.
DISCUSSION
We show here that RON is aberrantly expressed as a short form in some leukemic cell lines and primary AML samples. sfRON governs cell growth and survival and confers sensitivity to cMET inhibitors. Although flRON is expressed in cell lines and in most AML samples together with sfRON, several lines of evidence suggest that only the short form is constitutively activated in leukemic cells. Indeed, sfRON is the sole form to be: (i) constitutively phosphorylated independently of the RON ligand, (ii) interacting with and regulating Lyn, which drives cell growth in AML and (iii) not detected in normal CD34 þ cells suggesting an oncogenic pattern of expression. By using AZA that downregulates sfRON expression while sparing flRON expression, we have also demonstrated that selective inhibition of sfRON is associated with Lyn inhibition and decreased cell growth. In addition, the induction of sfRON expression after treatment with AZA in U937 cells and in AML specimens sensitized leukemic cells to SU-11274. Finally, specific knock down of sfRON in AML samples that did not express flRON induced a dephosphorylation of Lyn and a significant reduction of the clonogenic potential.
sfRON is known to conserve the two tyrosine residues within the carboxyl-terminus, which are required for the biological activities of RON. 5 It has been proposed that sfRON is a constitutively active, autophosphorylated protein that forms disulfide-linked dimers and confers growth advantage to cancer cells. 7 Although flRON is a strong inducer of both PI3-kinase and mitogen-activated protein kinase signaling pathways, our data distinct from that of ligand-dependent flRON. We also showed that mTORC1 targets were modulated by sfRON in accordance with our previous work showing that activated Lyn-induced mTORC1 activation without affecting the PI3-kinase/Akt pathway. 4 Moreover, Lyn and sfRON physically interact and regulate each other. As we also observed a diffuse localization pattern of sfRON in a similar way than activated Lyn, we speculate that Lyn and sfRON are engaged, probably with other unknown molecules, in a multiprotein signaling complex involved in the regulation of clonogenicity and survival of AML cells. sfRON also regulates the phosphorylation of BAD, which is inactivated in the vast majority of AML samples. 15 As a result, apoptosis was detected in leukemic cells after short-term incubations with cMET inhibitors.
The status of expression and the role of RON have been assessed in normal hematopoietic cells. The flRON mRNA has been detected in bone marrow cells, granulocytes but not in spleen nor in lymphocytes. 6 RON is expressed in intra-tissular macrophages but not circulating monocytes, and regulates inflammatory response. [17] [18] [19] RON also displays a role in the maturation of megakaryocytes via interleukin-6 production. 20 In normal CD34 þ cells, flRON is expressed at the protein level but its role in early hematopoiesis is still unclear. Of note, hematopoiesis was unaffected in mice with a germline ablation of the TK domain of RON. 19 However, it has been shown that the ligand of RON, hepatocyte growth factor-like, could have a myelosuppressive effect on early myeloid progenitors. 21 In our study, we also observed that flRON but not sfRON was expressed in normal CD34 þ and that cMET inhibitors were not toxic for CFU-GM growth. Thus, according to the cell context and its form of expression, RON can have opposite effects on the regulation of signaling pathways in normal hematopoietic cells as compared with leukemic cells. These results also suggest that the pattern of expression, intracellular localization and activity of oncogenic TKs in AML cells is probably more complex than mutations or overexpression as commonly described. 22 The regulation of expression of sfRON by methylation is still unclear in the literature. The modulation of sfRON expression by AZA is probably related to complex epigenetic regulations although indirect mechanisms are not excluded. Indeed, AZA, which is incorporated into both RNA and DNA, could also modulate other targets than epigenetic regulators that could contribute to this effect. Further detailed studies are needed to better understand these mechanisms that could be the basis for another study. However, our results indicate that AZA (whatever its mechanism of action) modulates the expression of sfRON but not flRON protein levels in leukemic cells. Indeed, it has been a useful tool to assess the cell signaling pathways modulated by sfRON. This unexpected regulation of TK networks by AZA in AML cells could also have an impact in clinic. Although AZA is increasingly used in patients with AML, almost all patients ultimately become resistant after a period of remission. Here, we have shown that in leukemic cells that do not express sfRON, AZA could induce the expression of sfRON and a strong signal of tyrosine phosphorylation that drive cell proliferation and sensitize cells to cMET inhibitors. Further investigations to analyze the impact of AZA on the global phosphoproteome using large scale methods, like mass spectrometry-based quantitative phosphoproteomics would provide the identification of new targets and signaling pathways dysregulated by this drug. 23 This could lead to uncover important informations on the antileukemic activity as well as mechanisms of resistance to AZA.
Our study supports the development of specific inhibitors of RON for the treatment of AML patients expressing sfRON. Consistent with 80% identity of the TK domain of RON and cMET, we observed a selective sensitivity of AML samples expressing sfRON to cMET inhibitors. Thus, cMET inhibitors currently assessed for other cancers should be evaluated in AML patients expressing this truncated form of RON.
